Department of Emergency Medicine, Taizhou Central Hospital (Taizhou University Hospital), Taizhou, Zhejiang, People's Republic of China.
Department of Radiotherapy, Taizhou Central Hospital (Taizhou University Hospital), No. 999 Donghai Road, Taizhou, 318000, Zhejiang, People's Republic of China.
Gen Thorac Cardiovasc Surg. 2022 Dec;70(12):1022-1031. doi: 10.1007/s11748-022-01840-4. Epub 2022 Jun 18.
This research is aimed to develop the prognostic nomogram and novel risk-scoring system for small cell lung cancer (SCLC) with different patterns of metastases.
Data on SCLC patients were extracted from the 2010-2015 Surveillance, Epidemiology, and End Results (SEER) database. This nomogram prognostic model was confirmed in the validation cohort. C-index and calibration curve were used to evaluate the accuracy of nomogram model. The predictive capability and net benefit of nomogram was estimated by decision curve analysis (DCA). The cut-off point of the risk stratification system based on nomogram was assessed by X-tile analysis.
Our Cox model indicated that age, gender, American Joint Committee on Cancer (AJCC) stage, metastases, chemotherapy, radiation and surgery were independent predictors for OS in SCLC patients. The C-index value of nomogram integrating significant variables for predicting OS in SCLC patients was 0.752 in SEER training set and 0.748 in SEER validation set, respectively. However, the TNM stage only had C-indexes of 0.464 and 0.472 for predicting OS, respectively. The nomogram prognostic model in this study showed higher C-indexes than those in the TNM stage. The C-index value and high quality of calibration plots indicate that the predictive ability of our nomogram model was of great superiority. DCA showed the nomogram had good clinical value. SCLC patients were further divided into low-risk and high-risk group according to nomogram predicted scores.
Our nomogram model that integrated significant factors can aid as an individualized clinical predictive tool in SCLC patients.
本研究旨在为不同转移模式的小细胞肺癌(SCLC)开发预后列线图和新的风险评分系统。
从 2010 年至 2015 年的监测、流行病学和最终结果(SEER)数据库中提取 SCLC 患者的数据。在验证队列中验证该列线图预测模型。C 指数和校准曲线用于评估列线图模型的准确性。通过决策曲线分析(DCA)评估列线图的预测能力和净收益。基于列线图的风险分层系统的截止点通过 X-tile 分析进行评估。
我们的 Cox 模型表明,年龄、性别、美国癌症联合委员会(AJCC)分期、转移、化疗、放疗和手术是 SCLC 患者 OS 的独立预测因素。列线图整合显著变量预测 SCLC 患者 OS 的 C 指数值在 SEER 训练集中分别为 0.752,在 SEER 验证集中分别为 0.748。然而,TNM 分期预测 OS 的 C 指数值分别为 0.464 和 0.472。本研究中的列线图预测模型的 C 指数值高于 TNM 分期。C 指数值和校准曲线的高质量表明,我们的列线图模型具有出色的预测能力。DCA 表明该列线图具有良好的临床价值。根据列线图预测评分,SCLC 患者进一步分为低风险和高风险组。
我们整合了显著因素的列线图模型可以作为 SCLC 患者的个体化临床预测工具。